Effects of androgen replacement on metabolism and physical performances in male hypogonadism

Journal of Endocrinological Investigation

Volumn 26, Issue 9, 2003, Pages 886-892

  Zitzman, M ^a   Nieschlag, Eberhard ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Androgen replacement; Male hypogonadism; Metabolism; Physical performance

Indexed keywords

ANDROGEN; GLUCOSE; GONADORELIN AGONIST; HEMOGLOBIN; INSULIN; LEPTIN; LIPID; TESTOSTERONE;

AGE; AGGRESSION; AGGRESSIVENESS; ANDROGEN THERAPY; BODY COMPOSITION; BODY EQUILIBRIUM; BODY FAT; BONE DENSITY; BONE TISSUE; CLINICAL TRIAL; DEPRESSION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DYSTHYMIA; ENDURANCE; ERYTHROPOIESIS; FITNESS; GAIT; GLUCOSE UTILIZATION; HEMOGLOBIN DETERMINATION; HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; INSULIN METABOLISM; INSULIN SENSITIVITY; LIPID METABOLISM; LIPID STORAGE; MALE; METABOLISM; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE GROWTH; MUSCLE MASS; MUSCLE TISSUE; OXYGEN SUPPLY; PATIENT MOBILITY; PATIENT MONITORING; PHYSICAL CAPACITY; PHYSICAL PERFORMANCE; REVIEW; STRENGTH; VASCULAR DISEASE;

EID: 0346368461     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03345240     Document Type: Review

References (74)

1. Wauters M, Considine R-V, Van Gaal L-F. Human leptin: From an adipocyte hormone to an endocrine mediator. Eur J Endocrinol 2000, 143: 293-311.
2. Behre H-M, Simoni M, Nieschlag E. Strong association between serum levels of leptin and testosterone in men. Clin Endocrinol 1997, 47: 237-40.
3. Büchter D, Behre H-M, Kliesch S, Nieschlag E. Effects of testosterone suppression in young men by the gonadotropin releasing hormone antagonist cetrorelix on plasma lipids, lipolytic enzymes, lipid transfer proteins, insulin, and leptin. Exp Clin Endocrinol Diabetes 1999, 107: 522-9.
4. Hislop M-S, Ratanjee B-D, Soule S-G, Marais A-D. Effects of anabolic-androgenic steroid use or gonadal testosterone suppression on serum leptin concentration in men. Eur J Endocrinol 1999, 141: 40-46.
5. Jockenhövel F, Blum WF, Vogel E, et al. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men. J Clin Endocrinol Metab 1997, 82: 2510-3.
6. Malmström R, Taskinen MR, Karonen SL, Yki-Järvinen H. Insulin increases plasma leptin concentrations in normal subjects and patients with NIDDM. Diabetologia 1996, 45: 1364-6.
7. Simon S, Charles MA, Nahoul K, et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J. Clin. Endocrinol Metab 1997, 82: 682-5.
8. Stellato R-K, Feldman H-A, Hamdy O, Horton E-S, McKinlay J-B Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: Prospective results from the Massachusetts male aging study. Diabetes Care 2000, 23: 490-4.
9. Oh J-Y, Barrett-Connor E, Wedick N-W, Wingard D-L. Endogenous sex hormones and the development of type 2 diabetes in older men and women: The Rancho Bernardo study. Diabetes Care 2002, 25: 55-60.
10. Marin P, Holmang S, Jonsson Sjostrom L, Kvist H, Holm G. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Rel Metab Dis 1992, 16: 991-7.
11. Hadigan C, Corcoran C, Stanley T, Piecuch S, Klibanski A, Grinspoon S. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: Relationship to body composition, gonadal function, and protease inhibitor use. J. Clin Endocrinol Metab 2000, 85: 35-41.
12. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: A meta-analysis. Am J Med 2001, 111: 261-9.
13. Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 2001, 281: E1172-81
14. Zitzmann M, Brune M, Kornmann B, Gromoll J, Junker R, Nieschlag E. The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. J Clin Endocrinol Metab 2001, 86: 4867-73.
15. Von Eckardstein A, Nofer JR, Assmann G. HDL and coronary heart disease: Role of cholesterol efflux and reverse cholesterol transport. Arterioscl. Thromb. Vasc Biol 2001, 20: 13-27.
16. Assmann G, Schulte H, Von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996, 124: 11-20.
17. Herbst KL, Samir SD, Bremner WJ, Amory JK. Testosterone significantly increases hepatic lipase activity and decreases high density lipoprotein cholesterol in three weeks in elderly men. Abstract P2-653 The Endocrine Society Meeting 2002.
18. Von Hartitzsch B, Kerr DN, Morley G, Marks B. Androgens in the anaemia of chronic renal failure. Nephron 1977, 18: 13-20.
19. Perretta M, Valladares L, Romero C, et al. Hormone action on the cell nucleus: Effect of erythropoietin and testosterone on bone marrow. Arch Biol Med Exp 1976, 10: 35-40.
20. Wang C, Swedloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 2000, 85: 2839-53.
21. Sih R, Morley JE, Kaiser FE, Perry HM III, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: A 12-month randomized controlled trial. J Clin Endocrinol Metab 1997, 82: 1661-7.
22. Liu PY, Wishart SM, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab 2002, 87: 3125-35.
23. Ly LP, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab 2001, 86: 4078-88.
24. Von Eckardstein S, Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: A phase II study. J Androl 2002, 23: 419-25.
25. Vermeulen A, Goemaere S, Kaufman JM. Testosterone, body composition and aging. J Endocrinol Invest 1999, 22: 110-6.
26. Khaw KT, Barrett-Connor E. Lower endogenous androgens predict central adiposity in men. Ann Epidemiol 1992, 2: 675-82.
27. Marin P, Arver S. Androgens and abdominal obesity. Baillieres Clin Endocrinol Metab 1998, 12: 441-51.
28. Vermeulen A, Kaufman JM, Giagulli VA. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab 1996, 81: 1821-6.
29. Marin P. Testosterone and regional fat distribution. Obesity Research 1995, 3: 609-12.
30. Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996, 81: 4358-65.
31. Behre HM, Von Eckardstein S, Kliesch S, Nieschlag E. Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years. Clin Endocrinol 1999, 50: 629-35.
32. Bhasin S, Storer TW, Berman N, Yarasheski KE, Cleveneger B, Casaburi RA. A replacement dose of testosterone increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 1997, 82: 407-13.
33. Rolf C, Von Eckardstein S, Koken U, Nieschlag E. Testosterone substitution of hypogonadal men prevents the age-dependent increases in body mass index, body fat and leptin seen in healthy ageing men: Results of a cross-sectional study. Eur J Endocrinol 2002, 146: 505-11.
34. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000, 85: 2670-7.
35. Woodhouse LJ, Nidhi G, Bhasin D, et al. Effects of testosterone dose on visceral, intermuscular and subcutaneous adipose tissue in healthy young men. Abstract OR 26-1 Endocrine Society Meeting 2002.
36. Garaulet M, Perex-Llamas F, Fuente T, Zamora S, Tebar FJ. Anthropometric, computed tomography and fat cell data in an obese population: Relationship with insulin, leptin, tumor necrosis factor-alpha, sex hormone-binding globulin and sex hormones. Eur J Endocrinol 2000, 143: 657-66.
37. Mauras N, Hayes V, Welch S, Veldhuis J, Urban R. Testosterone deficiency in young men: Marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 1998, 83: 1886-92.
38. Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men - A clinical research center study. J Clin Endocrinol Metab 1996, 81: 3469-75.
39. Sinha-Hikim I, Artaza J, Woodhouse L, et al. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am. J. Physiol. Endocrinol Metab 2002, 283: E154-E164.
40. Fukuda S, Iida H. Effects of orchidectomy on bone metabolism in beagle dogs. J Vet Med Science 2000, 62: 69-73.
41. Scopacasa F, Horowitz M, Wishart JM, Morris HA, Chatterton BE, Need AG. The relation between bone density, free androgen index, and estradiol in men 60 to 70 years old. Bone 2000, 27: 145-9.
42. Erben RG, Eberle J, Stahr K, Goldberg M. Androgen deficiency induces high turnover osteopenia in aged male rats a sequential histomorphometric study. J Bone Mineral Res 2000, 15: 1085-98.
43. Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink DJ Castrated men exhibit bone loss: Effect of calcitonin treatment on biochemical indices of bone remodeling. J Clin Endocr Metab 1989, 69: 523-7.
44. Leife E, Korner HC, Link TM, Behre HM, Peters PE, Nieschlag E. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebra body area and paraspinal muscle area in hypogonada men. Eur J Endocr 1998; 138: 51-8.
45. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997, 82: 2386-90.
46. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999, 84: 1966-72.
47. Wang C, Swerdloff RS, Iranmanesh A. Effects of transdermal T gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol 2001, 54: 739-50.
48. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal T on bone and muscle in older men with low bioavailable T levels. J Gerontol A Biol Sci Med Sci 2001; 56: M266-M272.
49. Zitzmann M, Brune M, Vieth V, Nieschlag E. Monitoring bone density in hypogonadal men with phalangeal ultrasound. Bone (in press).
50. Damien E, Price JS, Lanyon LE. Mechanical strain stimulates osteoblast proliferation through the estrogen receptor in males as well as females. J Bone Min Res 2000, 15: 2169-77.
51. Fohr B, Schulz A, Battmann A. Sex steroids and bone metabolism: Comparison of in vitro effects of 17beta-estradiol and testosterone on human osteosarcoma cell lines of various gender and differentiation. Exp Clin Endocrinol Diabetes 2000, 108: 414-23.
52. Ziegler R. Der Knochen und seine Erkrankungen, Teil II. Dtsch Med Wschr 1995, 120: 571-2.
53. Finkelstein JS. Androgens and bone metabolism. In: Nieschlag E, Behre HM (eds.), Testosterone: Action, Deficiency, Substitution 2nd ed. Berlin: Springer. 1998, p. 187.
54. Bellido T, Jilka RL, Boyce BF, et al. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor. J Clin Invest 1995, 95: 2886-95.
55. Gori F, Hofbauer LC, Conover CA, Khosla S. Effects of androgens on the insulin-like growth factor system in an androgen-responsive human osteoblastic cell line. Endocr. 1999, 140: 5579-86.
56. Aparicio LF, Jurkovic M, DeLullo J. Decreased bone density in ambulatory patients with duchenne muscular dystrophy. J Pediatr Orthop 2002, 22: 179-81.
57. Filaire E, Bernain X, Sagnol M, Lac G. Preliminary results on mood state, salivary testosterone: Cortisol ratio and team performance in a professional soccer team. Eur J Appl Physiol 2001, 86: 179-84
58. Schweiger U, Deuschle M, Weber B, et al. Testosterone gonadotropin and cortisol secretion in male patients with major depression. Psychosom Med 1999, 61: 292-6.
59. Unden F, Ljunggren JG, Beck-Friis J, Kjellman BF, Wetterberg L. Hypothalamic-pituitary-gonadal axis in major depressive disorders. Acta Psychiatr Scand 1988, 78: 138-46.
60. Seidman SN, Araujo AB, Roose SP, et al. Low testosterone levels in elderly men with dysthymic disorder. Am J Psychiatry 2002, 159: 456-9.
61. Barrett-Connor E, Von Mühlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: The Rancho Bernardo Study. J Clin Endocrinol Metab 1999, 84: 573-7.
62. Seidman S-N, Araujo A-B, Roose S-P, McKinlay J-B. Testosterone level, androgen receptor polymorphism, and depressive symptoms in middle-aged men. Biol Psychiatry 2001, 50: 371-6.
63. Burris AS, Banks SM, Carter CS, Davidson JM, Sherins RJ. A long-term prospective study of the physiologic and behavioural effects of hormone replacement in untreated hypogonadal men. J Androl 1992, 13: 297-304.
64. Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry 2000, 57: 141-7.
65. Zitzmann M, Nieschlag E. Testosterone levels in healthy men and the relation to behavioural and physical characteristics: Facts and constructs. Eur J Endocrinol 2001, 144: 183-97.
66. Pope HG Jr, Kouri EM, Hudson JI. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: A randomized controlled trial. Arch Gen Psychiatry 2000; 57: 133-40.
67. Christiansen K. Behavioural correlates of testosterone. Testosterone: Action Deficiency, Substitution 2nd ed. In: Nieschlag E, Behre HM (Eds.), 1998. p. 107.
68. Kouri EM, Lukas SE, Pope HG Jr, Oliva PS. Increased aggressive responding in male volunteers following the administration of gradually increasing doses of testosterone cypionate. Drug Alc Depend 1995, 40: 73-9.
69. Tricker R, Casaburi R, Storer TW, et al. The effects of supraphysiological doses of testosterone on angry behaviour in healthy eugonadal men - A clinical research center study. J Clin Endocrinol Metab 1996, 81: 3754-8.
70. O'Connor DB, Archer J, Hair WM, Wu FC. Exogenous testosterone, aggression, and mood in eugonadal and hypogonadal men. Physiol. Behav. 2002, 75: 557-66.
71. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999, 84: 2647-53.
72. Van Zyl CG, Noakes TD, Lambert MI. Anabolic-androgenic steroid increases running endurance in rats. Med Sci Sports Exerc 1995, 27: 1385-9.
73. Ekblom B, Holmberg HC, Eriksson K. Doping in endurance sports. Survey of individual Hb levels can expose doping. Lakartidningen 2001, Nov 28, 98: 5490-2, 5495-6.
74. Marin P, Krotkiewski M, Bjorntorp P. Androgen treatment of middle-aged, obese men: Effects on metabolism, muscle and adipose tissues. Eur J Med 1992, 1: 329-36.